<DOC>
	<DOC>NCT00932126</DOC>
	<brief_summary>This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients. The study will assess the compound's safety, the blood levels of PF-03758309 during the treatment and the effect of the compound on the tumor cells.</brief_summary>
	<brief_title>This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The study was prematurely terminated on 26Jul2011 due to the undesirable PK characteristics of PF-03758309 and the lack of an observed dose-response relationship. There were no safety concerns that contributed to the study termination.</detailed_description>
	<criteria>Advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available. ECOG (Eastern Cooperative Oncology Group) Performance Status (PS) must be 0 or 1. Adequate bone marrow, liver and kidney function. Patients with known brain metastases. Previous high dose chemotherapy requiring stem cell rescue. Prior irradiation to &gt;25% of the bone marrow. Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV). Current active treatment in another clinical study. Pregnancy or breast feeding. Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intraabdominal abscess within 6 months prior to study enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Phase 1 dose escalation dose finding pharmacokinetic and pharmacodynamic study</keyword>
</DOC>